chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Tdap and meningococcal were given at approximately 11:00am without incidence. Patient and mother then decided to do the HPV and at was given at 11:15am. Promptly after receiving the HPV vaccination patient became pale and stated she was dizzy. Patient then passed out while sitting in the chair and was safely brought to the floor. Patient remained out and her body became stiff and convulsed 2-3 times. Within 2 minutes patient woke up and was confused and scared. Saturations were checked at this time and were normal. Within 15 minutes patient was walking around and stated she felt fine.
Administered Yellow Fever vaccine via Intramuscular route in error.  Correct administration route is subcutaneous. Observed patient for 30 minutes.  Tolerated vaccine well. No adverse affect noted.  Advised to hydrate and take tylenol or ibuprofen for discomfort
Information has been received from a physician concerning a 74 year old female who on 27-MAR-2007 was vaccinated SC with a single dose of Zostavax ( Lot # 656413/1477F). On 03-APR-2007 the patient developed shingles all over the dorsal route around T10, T11, and T12. A product quality complaint was not involved. Additional information has been requested.
Atrial fibrillation; Blood in stool again for one time only after the 2nd dose/She also mentioned that she had blood in the stool twice, first time was after the first shot and second time after the Second shot.; This spontaneous case was reported by a consumer and describes the occurrence of ATRIAL FIBRILLATION (Atrial fibrillation) and HAEMATOCHEZIA (Blood in stool again for one time only after the 2nd dose/She also mentioned that she had blood in the stool twice, first time was after the first shot and second time after the Second shot.) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032B21A and 048A21A) for COVID-19 vaccination.     Concurrent medical conditions included Shellfish allergy and Chronic kidney disease (Improved). Concomitant products included HYDROCHLOROTHIAZIDE, IRBESARTAN (IRBESARTAN HYDROCHLOROTHIAZIDE), ROSUVASTATIN, AMLODIPINE from 06-Mar-2021 to an unknown date and ACETYLSALICYLIC ACID (ASPIRIN LOW) for an unknown indication.   On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced HAEMATOCHEZIA (Blood in stool again for one time only after the 2nd dose/She also mentioned that she had blood in the stool twice, first time was after the first shot and second time after the Second shot.) (seriousness criterion medically significant). On 21-Apr-2021, the patient experienced ATRIAL FIBRILLATION (Atrial fibrillation) (seriousness criterion medically significant). The patient was treated with APIXABAN (ELIQUIS) ongoing since an unknown date for Anticoagulant therapy, at a dose of UNK, bid. On 17-Apr-2021, HAEMATOCHEZIA (Blood in stool again for one time only after the 2nd dose/She also mentioned that she had blood in the stool twice, first time was after the first shot and second time after the Second shot.) had resolved. At the time of the report, ATRIAL FIBRILLATION (Atrial fibrillation) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant products included multivitamin.  The action taken with mRNA-1273 in response to the event was not applicable.  Company Comment:  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to MOD-2021-216141 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 30-Jun-2021: Follow-up received contains no new information. On 01-Jul-2021: Follow up received on 01-Jul-2021, no new information was recorded On 02-Jul-2021: Reporter details, patient details, medical history, concomitant drugs were added; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Day after receiving injection, arm painful and swollen. Febrile. Diagnosed with cellulitis and put on antibiotics.
Information has been received from a physician concerning a female patient with a history of shingles who on approximately 15-MAY-2007 was vaccinated SC with a dose of Zostavax (Oka/Merck). On an unspecified date in May 2007, the patient experienced "a little rash on her hand but there was no severe pain." Unspecified medical attention was sought. The patient's rash has cleared and she was doing fine and was considered recovered on an unspecified date in May 2007. A product quality complaint was not involved. Additional information has been requested. 09/24/07 This is in follow-up to report(s) previously submitted on 6/14/2007. Information has been received from a physician concerning a 65 year old female with hypertension, hyperlipidaemia, migraine, allergies to amitriptyline hydrochloride (MSD), MACRODANTIN, DARVOCET, CELEXA, PHENERGAN, atenolol (manufacturer unknown), and LEXAPRO and a history of shingles who on 09-MAR-2007 at 13:00 PM was vaccinated SC in the right deltoid with a first dose of ZOSTAVAX (Oka/Merck) (lot # 656606/0033U). There was no illness at the time of vaccination. On an unspecified date the patient experienced "a little rash on her hand but there was no severe pain". Unspecified medical attention was sought. The patient's rash has cleared and she was doing fine and was considered recovered. A product quality complaint was not involved. Additional information has been received from a registered nurse who reported that the patient broke out in a rash on the hand a few days after administration of the vaccine, on approximately 12-MAR-2007. It was noted to be a shingles-type rash. The symptoms resolved on their own. The patient was considered recovered on 20-MAR-2007. No diagnostic laboratory tests were performed. No further information is expected.
02.40pm swelling of eyes and across nasal bridge, o2 at 10 liters via 100% rebreather pulse ox 96%, pulse 160-170,B.P 112/62, no respiratory distress lungs clear airway clear. Benadryl 12.5mg I.M., 911 called,2:45pm.2:50pm.EMS here, Epinepherine 1:1000 0.3ml given by EMS. 2:55 Pt. transported via ambulance to hospital.  10/24/2008 MR received for DOS 10/21-22/2008 with D/C DX:  Anaphylactic reaction 2' to Flu vaccine. Static encephalopathy.  G-tube dependent. Pt presented to ER from PCP's office where pt developed immediate facial, eye, tongue and body swelling, difficulty breathing and agitation.  Epipen and Benadryl given on site and transported via EMS. Tx with Solumedrol and admitted for observation. PE (+) for periorbital edema and tongue enlargement. Pt did well and didn't require O2. D/C home next day.
On the way home I developed upper lip swelling followed by some right cheek swelling. At this point, I got really concerned ( maybe overly) but I pulled into a parking lot and called 911. I never had difficulty breathing and I had  a normal pulse oximetry. The fire department stayed with me for a while and it did not worsen, so I declined the ambulance ride and headed home.  The swelling lasted about 3 hours and resolved in reverse direction ( lip first, followed by the cheek)
3 days /p immun, DX case of Mumps by MD, 20 days /p immun, DX case of bilat otitis media-placed on antibiotic by MD, pt had no prior hx of otitis media
Pt. reported dizziness for less than 2 minutes while waiting in observation after vaccine.  She ate right before coming.  She was given a snack and water and waited another 15 minutes.  After 30 minutes she felt better.  Pt. instructed to go to the ED with any worsening or new concerning symptos.  Pt. verbalized understanding.
Migraine, fever (100.5 temp), chills, hot flashes, aches all over, tired
first dose of Shingrix in 12/2021, but he has not received the second dose yet; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 1st December 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.      Additional Information: GSK receipt date: 13-SEP--2022 Reporters comment:  The reporter reported that her husband (the patients) received the first dose of Shingrix but yet did not received the second dose The reporter did not consent to follow-up. No additional information was provided by the reporter. Additional Supportive information: The patient received the first dose of Shingrix but did not receive the second dose, which led to incomplete course of vaccination
Chills with no fever, no vomiting, loss of appetite, swollen arm in area of injection, rash on arm in area of injection, tired, and lack of energy.
COVID 19; COVID 19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 22-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 17Dec2021 as dose number unknown, single (Batch/Lot number: unknown) at the age of 21 years for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measure, PAXLOVID,  was taken as a result of drug ineffective, covid-19. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sudden onset of paresthesia, knee to foot, bilaterally and no improvement after 4 weeks
I had my vaccine at 08:15 in the morning and felt fine throughout the day.  I got home around 05;00 PM and started to feel lightheaded. I sat down and drank some water. I then got up and went to the restroom. As i was walking back from the bathroom I developed severe chest pain felt like I couldn?t breathe. According to my wife I collapsed and she immediately called 911. When they arrived I was completely out of it.  I started coming to in the ambulance. I can remember bits and pieces. My wife wasn?t allowed to come with me or be with me in the hospital due to COVID restrictions. I followed up the cardiologist and was diagnosed with costochondritis and was told to take ibuprofen 3x a day. I had been strongly advised to get the second shot and with the mandates quickly approaching even with my own and my wife?s apprehension I scheduled my second shot  There was no diagnosis stating that I had a reaction to the shot.  I held off as long as I could. My second shot was scheduled 08/19/21 at 08:15AM.  I felt fine through out the day but later in the evening I began to feel dizzy. I just went to sleep. In the morning I felt ok so I went to work and started my morning run. I then began to feel lightheaded had severe chest pain and felt like I couldn?t  breathe. I collapsed and again 911 was called.  I am still being advised to get the booster when necessary because ?the benefits out way the risks? states the cardiologist that seen me. I had no life threatening issues and all my tests came back normal. There was no damage noted from the tests.
Warm at injection site; Headache; Body aches; Fatigue; The patient received second dose vaccination on 13Apr2021 (within 15 days); This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 16:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. The patient medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included aciclovir (ACYCLOVIR), emtricitabine, tenofovir disoproxil fumarate (TRUVADA) and acetylsalicylic acid, caffeine, paracetamol (EXCEDRIN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Mar2021 at 15:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. On 14Apr2021 at 16:00, the patient experienced warm at injection site, headache, body aches and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events warm at injection site, headache, body aches and fatigue was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Its gotten worse, to the point of pain; Limited movement; Left shoulder (injection arm) has been sore; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 (at the age of 41-years-old) as a dose 2, single for COVID-19 immunization. Medical history included anxiety, depression, attention deficit disorder (ADD) and asthma. The patient had no known allergies. Concomitant medications included bupropion hydrochloride (WELLBUTRIN), fluoxetine hydrochloride (PROZAC), cetirizine hydrochloride (ZYRTEC), linum usitatissimum seed oil (FLAX OIL) and vitamin D (MANUFACTURER UNKNOWN), all taken for unspecified indications from unknown dates. Patient took historical vaccine that included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on unspecified date as a dose 1, single (UNKNOWN MANUFACTURER) for COVID-19 immunization. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Since the second shot on 25Apr2021, the patient experienced left shoulder (injection arm) soreness. On 16May2021, two weeks before the time of this report, the pain had gotten worse, to the point of pain and limited movement. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events left shoulder soreness with worsening pain and limited movement were not resolved at the time of this report.    This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
Very strong menstrual cycle - haven?t had one in at least 10 months and it was extremely heavy for one week.  Very close to going to ER.
Very sick; Wasn't felling good at all; Fever of a 101.1°F,temperature of  102.1°F; sore on her right arm; Felt tired; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Wasn't felling good at all), ILLNESS (Very sick), VACCINATION SITE PAIN (sore on her right arm), FATIGUE (Felt tired) and PYREXIA (Fever of a 101.1°F,temperature of  102.1°F) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032m20a and 039k20a) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Oct-2021, the patient experienced VACCINATION SITE PAIN (sore on her right arm) and FATIGUE (Felt tired). On 23-Oct-2021, the patient experienced VACCINATION COMPLICATION (Wasn't felling good at all) and PYREXIA (Fever of a 101.1°F,temperature of  102.1°F). On 24-Oct-2021, the patient experienced ILLNESS (Very sick). The patient was treated with PARACETAMOL (TYLENOL) on 23-Oct-2021 for Fever, Vaccination site pain and Fatigue, at an unspecified dose and frequency. At the time of the report, VACCINATION COMPLICATION (Wasn't felling good at all), ILLNESS (Very sick), VACCINATION SITE PAIN (sore on her right arm), FATIGUE (Felt tired) and PYREXIA (Fever of a 101.1°F,temperature of  102.1°F) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 23-Oct-2021, Body temperature: 101.1 (High) had a fever of a 101.1°F. On 24-Oct-2021, Body temperature: 102.1 (High) temperature of 102.1°F.         Concomitant medications include water pill and blood pressure medicine.   Treatment also include cold compresses for fever of a 101.1°F.
This report to VAERS provides the following narrative: A report has been received from VAERS (Health Authority) concerning 22 year old, male subject, who had been received FLUMIST (intranasal) started on 30-Oct-2006. It was reported that the patient experienced Guillain Barre Syndrome which started on 03-Dec-2006. Guillain Barre Syndrome 21-Dec-2006 records received and reviewed from reporter. GBS-with ascending peripheral hyposensation. CXR (chest X-ray) revealed pulmonary edema, GBS- trach for pneumonia, transferred to ECF for rehab. Numbness began in feet then tingling in hands extending to knee and elbows. Difficulty keeping right eye opened and difficulty swallowing. On 03-Dec-2006 ataxic gait. Decreased grip and strength in lower extremities. Annual follow up information indications status of recipient recovery still unknown. Lab data includes WBC 8.9, CT negative, CSF: RBC 28, Concentrated cytospins demonstrate mononuclear leukocytes. Protein 21, glucose 54, culture negative, prealbumin 10.6, albumin 51.7, Alpha 1 G 5.6, Alpha 2 G 937, Beta G 16.1, Gamma G 6.4. All cultures negative. WBC ranged from 8.7-18.6. The outcome of the event of Guillain Barre Syndrome was unknown. The reporter considered the event Guillain Barre Syndrome to be serious due to hospitalization.
Raised, red area- 7 1/2 x 5 cm.  Patient advised to take ADVIL and ice are.  Patient to follow-up if worsens.
I started that night exp fatigue. the next morning sore throat, body ache,fever 102 and got tested for Covid following week results negative)
Pt felt dizzy, warm, B/P 110/80 - 70-24 - Continued for > 10 minutes. Rescue called - Refused to go to hospital - ice applied, ice H2O given, 111/50- 70-22 - Left with friend.
No signs or symptoms of an adverse event noted. Vaccines were given per mothers request. After administration the patient informed us that she was pregnant.
felt a little bit uncomfortable; Fever of 103/temperature of 103 F; This spontaneous case was reported by a patient and describes the occurrence of DISCOMFORT (felt a little bit uncomfortable) and PYREXIA (Fever of 103/temperature of 103 F) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history provided by reporter.  Concomitant products included DIAZEPAM, GABAPENTIN, LEVOTHYROXINE, GLICLAZIDE (MICROZIDE [GLICLAZIDE]), MORPHINE SULFATE (MS CONTIN) and ATORVASTATIN for an unknown indication.   On 02-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DISCOMFORT (felt a little bit uncomfortable) and PYREXIA (Fever of 103/temperature of 103 F). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at an unspecified dose and frequency. At the time of the report, DISCOMFORT (felt a little bit uncomfortable) and PYREXIA (Fever of 103/temperature of 103 F) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Pyrexia: 103 (High) 103.         Concomitant medication also included Promapar twice a day.   Most recent FOLLOW-UP information incorporated above includes: On 19-Jul-2021: Event discomfort, concomitant medications, start date and anatomical location for the suspect vaccination, treatment medication for the event fever all were added.
20MAY pt experienced rhinitis, sore throat, cough, ankle/knee pain, purpuric rash; 22MAY dx Schonleiu synd by MD; 23MAY rx: PCN; 27MAY complete resolution;
Patient received vaccine and later that night, stated her arm at inj site was "hard as a rock", reddened, has a rash, and arm is achy. Rash is raised, and is from elbow up 3-4 inches.
pain; This case was reported by a consumer via interactive digital media and described the occurrence of pain in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced pain. On an unknown date, the outcome of the pain was unknown.   It was unknown if the reporter considered the pain to be related to Shingrix.  Additional details were reported as follows: This case was reported by a consumer via media and described the occurrence of adverse drug reaction in a patient who received Herpes zoster (Shingrix for prophylaxis. The reporter wanted to know what would be best for pain after getting side effects from Shingrix vaccine.
Dates of injections were 01/06/2021 & 02/02/2021 - 27 days apart.  Covid symptoms 21 days after second dose.  Diagnosed ?positive SARS COVID 19 coronavirus (SARS-CoV-2)? by PCR/molecular test administered 02/24/2021 (day after symptom onset).
Child presented to clinic day following immunizations. Both administered to (R) deltoid. (R) upper arm has 12 x 12 cm warm, red and indurated area around the site. Advised ice, BENADRYL and 2.5% hydrocortisone ointment.